Enzyme is Crucial for Combatting Antibiotic-Resistant E. coli Infections

Article

Research by bioscientists at the University of Kent and the University of Queensland is expected to pave the way for new approaches to kill bacteria that no longer respond to conventional antibiotics. In a paper published by Scientific Reports, Kent's Dr. Mark Shepherd and colleagues demonstrate the importance of an enzyme, cytochrome bd-I, for survival of E. coli that is resistant to multiple antibiotics.

Cytochrome bd-I tagged with Green Fluorescent Protein can be visualized in the membrane of E. coli. Courtesy of Dr. Mark Shepherd
 
Research by bioscientists at the University of Kent and the University of Queensland is expected to pave the way for new approaches to kill bacteria that no longer respond to conventional antibiotics. In a paper published by Scientific Reports, Kent's Dr. Mark Shepherd and colleagues demonstrate the importance of an enzyme, cytochrome bd-I, for survival of E. coli that is resistant to multiple antibiotics.

E. coli causes serious conditions including sepsis, bladder infections, kidney failure and dysentery. The human immune system produces nitric oxide to kill invading E. coli, and cytochrome bd-I is shown to provide significant resistance to nitric oxide during infection.

Since cytochrome bd-I is absent in humans, drugs designed to target this enzyme are less likely to be toxic to human cells. In future, targeting cytochrome bd-I with new drugs will render antibiotic-resistant bacteria more susceptible to attack from the host immune system.

Shepherd is a lecturer in microbial biochemistry at Kent's School of Biosciences.

Source: University of Kent

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
In a recent discussion with Infection Control Today® (ICT®), study authors Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio, shared their insights on how the project evolved and what the findings mean for the future.